CARLSBAD, Calif., Sept. 9,
2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.
(Nasdaq: IONS) today announced the pricing of an underwritten
public offering of 11,500,000 shares of its common stock. The
shares of common stock are being sold at a public offering price of
$43.50 per share. The aggregate gross
proceeds to Ionis from this offering are expected to be
approximately $500.3 million, before
deducting underwriting discounts and commissions and other
estimated offering expenses payable by Ionis. Ionis has granted the
underwriters a 30-day option to purchase up to an additional
1,725,000 shares of its common stock at the public offering price
per share, less underwriting discounts and commissions.
The offering is expected to close on September 11, 2024, subject to the satisfaction
of customary closing conditions.
Ionis intends to use the net proceeds from the offering to fund
its independent commercial launches, late-stage clinical programs,
earlier pipeline programs, and research and development activities,
as well as for working capital and general corporate purposes.
Morgan Stanley and Goldman Sachs & Co. LLC are acting as
joint book-running managers for the offering.
A shelf registration statement relating to the offered
securities was filed with the Securities and Exchange Commission
("SEC") on November 24, 2023, and was
automatically effective upon filing. The offering is being made
only by means of a written prospectus and prospectus supplement
that form a part of the registration statement. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering has been filed, and a final prospectus supplement and
accompanying prospectus relating to the offering will be filed with
the SEC and will be available for free on the SEC's website,
located at www.sec.gov. Copies of the preliminary prospectus
supplement, the accompanying prospectus and, when available, the
final prospectus supplement relating to this offering may be
obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus
Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at
prospectus@morganstanley.com; and Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at
(866) 471-2526, or by email at prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring
better futures to people with serious diseases. Ionis currently has
five marketed medicines and a leading pipeline in neurology,
cardiology, and other areas of high patient need. As the pioneer in
RNA-targeted medicines, Ionis continues to drive innovation in RNA
therapies in addition to advancing new approaches in gene editing.
A deep understanding of disease biology and industry-leading
technology propels our work, coupled with a passion and urgency to
deliver life-changing advances for patients.
Forward-looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include statements
regarding, among other things, Ionis' expectations regarding the
completion and timing of the offering, the gross proceeds Ionis
expects to receive from the offering and Ionis' anticipated use of
the net proceeds from the offering. Any statement describing Ionis'
goals, expectations, financial or other projections, intentions, or
beliefs is a forward-looking statement and should be considered an
at-risk statement. Words such as "expected," "intend," "will," and
similar expressions are intended to identify forward-looking
statements. These and other risks are described in additional
detail in filings that Ionis makes with the SEC from time to time,
including Ionis' annual report on Form 10-K for the year ended
December 31, 2023, its subsequently
filed quarterly reports on Form 10-Q, the preliminary prospectus
supplement related to the offering and the final prospectus
supplement to be filed with the SEC. Such statements are subject to
certain risks and uncertainties, including, but not limited to,
those related to Ionis' business and macroeconomic and geopolitical
events. Ionis' forward-looking statements also involve assumptions
that, if they never materialize or prove correct, could cause its
results to differ materially from those expressed or implied by
such forward-looking statements. Although Ionis' forward-looking
statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by
Ionis. Except as required by law, Ionis undertakes no obligation to
update any forward-looking statements for any reason. As a result,
you are cautioned not to rely on these forward-looking
statements.
Ionis Pharmaceuticals Investor Contact:
D.
Wade Walke, Ph.D. – IR@ionis.com –
760-603-2331
Ionis Pharmaceuticals Media Contact:
Hayley Soffer – media@ionis.com –
760-603-4679
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ionis-announces-pricing-of-500-3-million-public-offering-302242763.html
SOURCE Ionis Pharmaceuticals, Inc.